There has been a positive outcome from the first collaborative assessment by regulators taking part in an international pilot exploring how to make it easier for drug companies to make post-approval manufacturing changes in different countries and ensure the supply of critical medicines.
The assessment, which involved US and EU regulators evaluating an application to add new manufacturing and quality control sites for a oncology biologic, was completed under the four-month goal window for a standard manufacturing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?